Clinical use of combined detection with tumor marikers For pancreatic cancer

摘要

Objective To explore the value of clinical use of combined detection with tumor markers for pan- creatic cancer. Methods Tumor markers CA242, CA19-9 and CA50 in serum of 32 patients with pancreatic cancer; 26 patients with non-pancreatic digestive tract cancers and 24 patients with benign pancreatic or biliary tract diseases were measured by immunoradiometric assay (IRMA). Results The levels of three markers in serum and positive rates of patients with pancreatic cancer were higher than those of other patients.